*ncbi.life
			MedGen

  Source:		MedGen UID: 1649258


     		Remdesivir

			Related Concepts
			GS-5734
			lopinavir
			ritonavir
			COVID-19
			SARS-CoV-2
			severe acute respiratory syndrome
			ribavirin
			Middle East respiratory syndrome
			antiviral
			chloroquine
			hydroxychloroquine
			favipiravir
			tocilizumab

			PubMed
			32336586 Pharmacotherapy in COVID-19; A
			narrative review for emergency providers.

			32309622 Emerging Therapeutic Strategies
			for COVID-19 patients.

			32307245 Treatment options for COVID-19:
			The reality and challenges.

			32294562 A search for medications to treat
			COVID-19 via in silico molecular docking models
			of the SARS-CoV-2 spike glycoprotein and
			3CL protease.

			32283108 Remdesivir and SARS-CoV-2:
			Structural requirements at both nsp12 RdRp
			and nsp14 Exonuclease active-sites.

			32280433 Predicting commercially available
			antiviral drugs that may act on the novel coronavirus
			(SARS-CoV-2) through a drug-target interaction
			deep learning model.

			32277040 Structure of the RNA-dependent
			RNA polymerase from COVID-19 virus.

			32258351 Current knowledge about the antivirals
			remdesivir (GS-5734) and GS-441524 as
			therapeutic options for coronaviruses.

			32256547 Clinical trials on drug repositioning
			for COVID-19 treatment.

			32253226 An orally bioavailable broad-spectrum
			antiviral inhibits SARS-CoV-2 in human airway
			epithelial cell cultures and multiple coronaviruses
			in mice.

			32251767 Remdesivir, lopinavir, emetine, and
			homoharringtonine inhibit SARS-CoV-2
			replication in vitro.

			32247927 Remdesivir for severe acute respiratory syndrome
			coronavirus 2 causing COVID-19: An evaluation
			of the evidence.

			32247050 Insight into 2019 novel coronavirus
			- an updated intrim review and lessons from
			SARS-CoV and MERS-CoV.

			32094225 The antiviral compound remdesivir
			potently inhibits RNA-dependent RNA polymerase
			from Middle East respiratory syndrome coronavirus.

			32081636 Severe acute respiratory syndrome
			coronavirus 2 (SARS-CoV-2) and
			coronavirus disease-2019 (COVID-19):
			The epidemic and the challenges.

			32054787 Prophylactic and therapeutic remdesivir
			(GS-5734) treatment in the rhesus macaque
			model of MERS-CoV infection.

			32023685 [Potential antiviral therapeutics for
			2019 Novel Coronavirus].

			32022370 Learning from the Past: Possible
			Urgent Prevention and Treatment Options for
			Severe Acute Respiratory Infections Caused by
			2019-nCoV.

			32020029 Remdesivir and chloroquine
			effectively inhibit the recently emerged novel
			coronavirus (2019-nCoV) in vitro.

			31774950 A Randomized, Controlled Trial of
			Ebola Virus Disease Therapeutics.

			31389664 New Nucleoside Analogues for the
			Treatment of Hemorrhagic Fever Virus
			Infections.

			31233808 Broad spectrum antiviral remdesivir
			inhibits human endemic and zoonotic
			deltacoronaviruses with a highly divergent RNA
			dependent RNA polymerase.

			30974127 Advances in respiratory virus
			therapeutics - A meeting report from the 6th
			isirv Antiviral Group conference.

			29511076 Coronavirus Susceptibility to the Antiviral
			Remdesivir (GS-5734) Is Mediated by the Viral
			Polymerase and the Proofreading Exoribonuclease.

			Clinical Trials
			4302766 Expanded Access Remdesivir (RDV;
			GS-5734™)

			4292899 Study to Evaluate the Safety and
			Antiviral Activity of Remdesivir (GS-5734™) in
			Participants With Severe Coronavirus Disease
			(COVID-19) (Not yet recruiting)

			4292730 Study to Evaluate the Safety and
			Antiviral Activity of Remdesivir (GS-5734™) in
			Participants With Moderate Coronavirus
			Disease (COVID-19) Compared to Standard of
			Care Treatment (Not yet recruiting)

			4280705 Adaptive COVID-19 Treatment Trial
			(Recruiting)

			4257656 Severe 2019-nCoV Remdesivir RCT

			4252664 Mild/Moderate 2019-nCoV Remdesivir RCT

			3719586 Investigational Therapeutics for the Treatment
			of People With Ebola Virus Disease

     		                         Embed       Tweet       Print